← Leaderboards
Petr B. Makhov
Research Inst Of Fox Chase Can Ctr
$1,568,231
Attributed
$1,568,231
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $483.4K · FY2018–24$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,568,231 · 5
By mechanism
R21$1,198,231 · 3
R03$370,000 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseExperimental StudyTumorBindingPharmaceutical PreparationsProgression-Free SurvivalsClear CellXenograft ModelAntibodiesIncidenceRenal Cell CarcinomaBaseDesignDosePropertyLigandsInterruptionMalignant NeoplasmsHuman ModelCombinatorialClear Cell Renal Cell CarcinomaAffinityImmunotherapeutic AgentImmunotherapy
Grant awards (8)
A novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal cancer$483,395
R21 · FY2024 · CA · contact PI
Tumor-specific anti-angiogenic anti-CD70-FGF/VEGF-trap fusion antibodies for renal cancer therapy$258,397
R21 · FY2023 · CA · contact PI
Tumor-specific anti-angiogenic anti-CD70-FGF/VEGF-trap fusion antibodies for renal cancer therapy$219,725
R21 · FY2022 · CA · contact PI
Novel anti-CD70-VEGF-trap fusion antibodies as a next-generation therapeutic approach for renal cancer$93,500
R03 · FY2021 · CA · contact PI
Novel anti-CD70-VEGF-trap fusion antibodies as a next-generation therapeutic approach for renal cancer$93,500
R03 · FY2020 · CA · contact PI
Targeting Musashi-2 (MSI2) regulation of EGFR and HER2 in lung cancer$236,714
R21 · FY2019 · CA · contact PI
Disrupting lysosomal sequestration of sunitinib by farnesyl-transferase inhibitors as a next generation therapeutic approach for TKI resistant RCC$91,500
R03 · FY2019 · CA · contact PI
Disrupting lysosomal sequestration of sunitinib by farnesyl-transferase inhibitors as a next generation therapeutic approach for TKI resistant RCC$91,500
R03 · FY2018 · CA · contact PI